Bank of America Corp DE Decreases Stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Bank of America Corp DE trimmed its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 22.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 899,838 shares of the biotechnology company's stock after selling 261,127 shares during the period. Bank of America Corp DE owned approximately 0.43% of BioCryst Pharmaceuticals worth $6,767,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the stock. Vanguard Group Inc. grew its stake in shares of BioCryst Pharmaceuticals by 7.8% in the fourth quarter. Vanguard Group Inc. now owns 21,890,422 shares of the biotechnology company's stock valued at $164,616,000 after buying an additional 1,583,826 shares in the last quarter. Caligan Partners LP grew its holdings in shares of BioCryst Pharmaceuticals by 16.0% during the fourth quarter. Caligan Partners LP now owns 2,995,932 shares of the biotechnology company's stock worth $22,529,000 after purchasing an additional 412,347 shares during the last quarter. Northern Trust Corp boosted its holdings in BioCryst Pharmaceuticals by 7.7% in the fourth quarter. Northern Trust Corp now owns 2,004,911 shares of the biotechnology company's stock valued at $15,077,000 after acquiring an additional 143,986 shares during the last quarter. Eversept Partners LP lifted its stake in BioCryst Pharmaceuticals by 269.9% in the fourth quarter. Eversept Partners LP now owns 1,980,312 shares of the biotechnology company's stock valued at $14,892,000 after buying an additional 1,444,907 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its stake in BioCryst Pharmaceuticals by 4.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,979,992 shares of the biotechnology company's stock valued at $14,890,000 after buying an additional 91,998 shares during the period. 85.88% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on BCRX shares. JPMorgan Chase & Co. upped their target price on BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the stock an "overweight" rating in a research report on Tuesday, May 6th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $13.00 target price (up from $11.00) on shares of BioCryst Pharmaceuticals in a research report on Tuesday, May 6th. HC Wainwright reiterated a "buy" rating and set a $30.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, May 6th. Cantor Fitzgerald started coverage on BioCryst Pharmaceuticals in a research note on Tuesday, April 29th. They set an "overweight" rating and a $20.00 price target for the company. Finally, Wall Street Zen upgraded BioCryst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Thursday, May 22nd. One research analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, BioCryst Pharmaceuticals presently has an average rating of "Buy" and an average price target of $16.56.

BioCryst Pharmaceuticals Trading Down 1.1%

Shares of BCRX traded down $0.13 during trading hours on Friday, reaching $10.76. 1,377,373 shares of the company's stock traded hands, compared to its average volume of 3,024,684. The stock has a market cap of $2.25 billion, a PE ratio of -17.63 and a beta of 1.08. The firm's 50 day simple moving average is $8.61 and its 200-day simple moving average is $8.13. BioCryst Pharmaceuticals, Inc. has a 12 month low of $5.92 and a 12 month high of $11.11.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last announced its quarterly earnings data on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.06). The company had revenue of $131.50 million during the quarter, compared to the consensus estimate of $126.64 million. The company's quarterly revenue was up 40.8% compared to the same quarter last year. During the same quarter last year, the company posted $0.28 earnings per share. As a group, analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current fiscal year.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.